CareDx “Neutral” Rating (CDNA) Confirmed at HC Wainwright

HC Wainwright maintained its neutral rating on the stock CareDx (NASDAQ:CDNA – Free Report) in a report published on Friday, Benzinga reports.

CDNA has been the subject of many other reports. StockNews.com downgraded CareDx from buy to hold in a research note on Wednesday. In a report on Monday, May 13, Raymond James downgraded CareDx from an Outperform rating to a Market Perform rating. Craig Hallum increased their price target on CareDx from $15.00 to $22.00 and gave the company a “buy” rating in a report on Friday, May 17th. Stephens increased their price target on CareDx from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Monday, May 13th. Finally, Goldman Sachs Group increased their price target on CareDx from $10.00 to $14.00 and gave the company a “buy” rating in a report on Monday, May 13th. Three analysts gave a hold rating and three gave a buy rating. Based on data from MarketBeat, CareDx currently has a consensus rating of Buy on average and an average price target of $16.50.

Check out our latest stock report on CareDx

CareDx Volume Down 3.8%

NASDAQ CDNA stock opened at $13.01 on Friday. The market value of the company’s shares is $677.56 million, the P/E ratio is -3.80 and the beta coefficient is 1.51. CareDx has a 12 month low of $4.80 and a 12 month high of $17.03. The company’s fifty-day simple moving average is $11.07 and its 200-day simple moving average is $10.45.

CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly data on Thursday, May 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, which was $0.18 above the consensus estimate of ($0.46). CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. The company’s revenue for the quarter was $72.05 million, compared to analyst expectations of $63.63 million. On average, equity analysts forecast that CareDx will see -1.49 EPS for the current fiscal year.

Hedge funds influence CareDx

Institutional investors have recently increased or decreased their holdings in the stock. Headlands Technologies LLC acquired a new position in CareDx during the fourth quarter valued at approximately $50,000. Nisa Investment Advisors LLC increased its position in CareDx by 442.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock valued at $77,000 after acquiring an additional 5,253 shares during the period. Quest Partners LLC acquired a new position in CareDx during the fourth quarter worth approximately $117,000. WINTON GROUP Ltd acquired a new position in CareDx during the 3rd quarter valued at approximately $72,000. Finally, Cetera Trust Company NA acquired a new position in CareDx during the fourth quarter valued at approximately $142,000.

CareDx company profile

(Get the free report)

CareDx, Inc is committed to discovering, developing and commercializing diagnostic solutions for transplant patients and their caregivers in the United States and around the world. It also provides AlloSure Kidney, a cell-free donor-derived DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Featured Stories

Get CareDx news and ratings every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings on CareDx and related companies with MarketBeat.com’s FREE daily email newsletter.